Characteristics of Included Studies (Question 3)

Nazila Assasi; Gordon Blackhouse; Kaitryn Campbell; Katherine Gaebel; Robert Hopkins; Jathishinie Jegathisawaran; Alison Sinclair; Kelsey Seal; Chris Kamel; Mitchell Levine; Gordon Blackhouse; Bernice Tsoi; Kaitryn Campbell; Jathishinie Jegathisawaran; Laura Weeks; Sarah Garland; Kristen Moulton; David Kaunelis

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Assasi N, Blackhouse G, Campbell K, et al. DNA Mismatch Repair Deficiency Tumour Testing for Patients With Colorectal Cancer: A Health Technology Assessment [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug. (CADTH Optimal Use Report, No. 5.3b.)

Cover of DNA Mismatch Repair Deficiency Tumour Testing for Patients With Colorectal Cancer: A Health Technology Assessment

DNA Mismatch Repair Deficiency Tumour Testing for Patients With Colorectal Cancer: A Health Technology Assessment [Internet].

Show details

Contents

< Prev Next >

Appendix 26Characteristics of Included Studies (Question 3)

Author	Country	Initial Study Population	BRAF-PCR Test Method	Hypermethylation Test Method	BRAF-PCR		BRAF-IHC		Hypermethylation
Author	Country	Initial Study Population	BRAF-PCR Test Method	Hypermethylation Test Method	sens	spec	sens	spec	sens	spec
Toon 2013⁶⁹	Australia	1,403 CRC patients, BRAF-PCR and IHC completed on all patients. 51 CRC samples from a registry used for methylation status	Sequencing	Method not reported	x	x	x	x	x	x
Bouzourene 2010⁷²	Switzer-land	Selected patients known to have MLH1 mutation + patients known to have sporadic CRC but loss of MLH1	Sequencing	Single-strand conformation analysis	x	x			x	x
Chang 2010⁷⁷	Taiwan	561 CRC patients had MSI. IHC conducted on 158 patients who were MSI high or met BG criteria	Sequencing	MS-PCR	x	x			x	x
Perez-Carbonell 2010¹⁶	Spain	IHC performed on 2,265 CRC tumours	Sequencing	Bisulfite genomic sequencing (MethyLight & SALSA)	x	x			x	x
Aleayehu 2008⁷⁶	Slovakia	22 patients who fulfilled AC, BG, or rBG criteria, plus 1 patient that was MSI high but did not fill criteria, plus 10 MSS patients	No BRAF sequencing	Bisulfite genomic sequencing						x
Hampel 2008⁶¹	USA	500 CRC tumours from patients treated in 6 hospitals had IHC	No BRAF sequencing	MS-PCR & COBRA					x	x
Julie 2008⁷⁴	France	214 consecutive CRC patients tested for MSI. Tumours that were MSI high, had IHC testing (n = 21)	Sequencing	Bisulfite genomic sequencing (COBRA)	x	x			x	x
Poynter 2008⁷¹	USA/Canada	1,222 CRC patients from 6 registries. IHC conducted in all MSI-H and MSI-L patients (n = 719)	No BRAF sequencing	Bisulfite genomic sequencing (MethyLight)					x
Rahner 2008⁷³	Germany	763 CRC patients who fulfilled at least one of the rBG criteria	Sequencing	Bisulfite genomic sequencing (COBRA)					x	x
Loughrey 2007⁶⁸	Australia	500 CRC tumours that were suspected to be HNPCC. 68 patients were MSI high or IHC deficient	allele-specific PCR + Sequencing	No hypermethylation test	x	x
Overbleek 2007⁷⁵	Nether-lands	667 tumours from family members suspected for Lynch syndrome because they either met the AC or the BG criteria or had history very close to the BG	No BRAF sequencing	Bisulfite genomic sequencing (MethyLight)						x
Wang 2003⁷⁰	USA	293 consecutive tumours tested for MSI and IHC	Sequencing	Bisulfite genomic sequencing	x	x

: AC = Amsterdam criteria; BG = Bethesda Guidelines; COBRA = combined bisulphite restriction analysis; CRC = colorectal cancer; HNPCC = hereditary non-polyposis colorectal cancer; IHC = immunohistochemistry; MSI = microsatellite instability; MS-PCR = methylation-specific polymerase chain reaction; PCR = polymerase chain reaction; rBG = revised Bethesda criteria; sens = sensitivity; spec = specificity.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK384818

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Assasi N, Blackhouse G, Campbell K, et al. DNA Mismatch Repair Deficiency Tumour Testing for Patients With Colorectal Cancer: A Health Technology Assessment [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug. (CADTH Optimal Use Report, No. 5.3b.) Appendix 26, Characteristics of Included Studies (Question 3)
PDF version of this title (6.5M)

Other titles in this collection

CADTH Optimal Use Reports

Recent Activity

Clear Turn Off Turn On

Characteristics of Included Studies (Question 3) - DNA Mismatch Repair Deficienc...
Characteristics of Included Studies (Question 3) - DNA Mismatch Repair Deficiency Tumour Testing for Patients With Colorectal Cancer: A Health Technology Assessment

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Bookshelf

DNA Mismatch Repair Deficiency Tumour Testing for Patients With Colorectal Cancer: A Health Technology Assessment [Internet].

Appendix 26Characteristics of Included Studies (Question 3)

Views

Other titles in this collection

Recent Activity